CN101671278B - 氨基甲酸紫草素酯及其制备方法和用途 - Google Patents
氨基甲酸紫草素酯及其制备方法和用途 Download PDFInfo
- Publication number
- CN101671278B CN101671278B CN2009101531399A CN200910153139A CN101671278B CN 101671278 B CN101671278 B CN 101671278B CN 2009101531399 A CN2009101531399 A CN 2009101531399A CN 200910153139 A CN200910153139 A CN 200910153139A CN 101671278 B CN101671278 B CN 101671278B
- Authority
- CN
- China
- Prior art keywords
- ester
- methyl
- naphthoquinones
- dihydroxyl
- pentenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 title claims abstract description 44
- -1 Carbamic acid alkannin ester Chemical class 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000004229 Alkannin Substances 0.000 title abstract description 12
- 235000019232 alkannin Nutrition 0.000 title abstract description 12
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 title abstract 8
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 claims abstract description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 238000004440 column chromatography Methods 0.000 claims abstract description 5
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 241001071917 Lithospermum Species 0.000 claims description 32
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 14
- LIJLYNWYKULUHA-UHFFFAOYSA-N 2-chloroethyl carbamate Chemical compound NC(=O)OCCCl LIJLYNWYKULUHA-UHFFFAOYSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 206010059866 Drug resistance Diseases 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 239000012948 isocyanate Substances 0.000 abstract 1
- 150000002513 isocyanates Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- HXBYBCASAVUYKF-GVYWOMJSSA-N (4r,5s,6r,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HXBYBCASAVUYKF-GVYWOMJSSA-N 0.000 description 1
- JMELRMJNKRXCFL-UHFFFAOYSA-N 5,8-dihydronaphthalene-1,2-dione Chemical class C1(C(C=CC=2CC=CCC12)=O)=O JMELRMJNKRXCFL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 235000004256 Buglossoides arvense Nutrition 0.000 description 1
- 0 CC(C)=CC[C@](C(C(c(c1c(cc2)O)c2O)=O)=CC1=*)OC(N*)=O Chemical compound CC(C)=CC[C@](C(C(c(c1c(cc2)O)c2O)=O)=CC1=*)OC(N*)=O 0.000 description 1
- 241000118841 Lithospermum incisum Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种氨基甲酸紫草素酯及其制备方法和用途。它是1摩尔紫草素和1~2摩尔的异氰酸酯在甲苯中反应,反应温度为80~100℃,反应时间为10~15小时,柱层析分离得到氨基甲酸紫草素酯。氨基甲酸紫草素酯用于制备具有抗肿瘤活性以及耐药性的药物。本发明通过简单易行的方法制备氨基甲酸紫草素酯,并对氨基甲酸紫草素酯进行抗肿瘤活性和耐药性进行考察,发现其对肿瘤细胞株具有强烈的抑制作用,并证明具有很好的耐药性,是具有前途的抗肿瘤药物。
Description
技术领域
本发明涉及化合物及其制备方法,尤其涉及一种氨基甲酸紫草素酯及其制备方法和用途。
背景技术
5,8-二氢萘醌类化合物已被美国国家癌症研究所确定为具有抗肿瘤活性的物质,紫草素(SH)是该类化合物的典型代表。紫草素具有广泛的生物活性包括:抗菌、抗艾滋病、促进烧伤伤口愈合、抗肿瘤等,备受研究者的关注。近年来对对紫草素的研究主要关注于以下的方面:紫草素的新药效研究,紫草素的全合成和对紫草素改性衍生化等研究。
本身抗肿瘤活性较弱且水溶性不佳等因素使得紫草素不能成为很好的抗肿瘤药物,为此很多研究者对紫草素进行了修饰,合成了多类紫草素衍生物。研究表明5,8-二氢萘醌结构是紫草素抗肿瘤活性的关键,因此绝大部分的紫草衍生物都是1’-位羟基进行修饰的,这类衍生物比紫草素本身具有更好的抗肿瘤活性,如1’-O-乙酰紫草素,1’-O-呋喃甲酰紫草素,1’-O-异戊酰紫草素,侧链氮原子取代的紫草素类似物。
1.V.P.Papageorgiou,A.N.Assimopoulou,E.A.Couladouros,D.Hepworth,K.C.Nicolaou.Angew.Chem.Int.Ed.1999,38,270.
2.W.J.Wang,J.Y.Bai,D.P.Liu,L M..Xue,X.Y.Zhu.Yaoxue Xuebao,1994,29,161
3.Q.Lu,W.J.Liu,J.Ding,J.C.Cai,W.H.Duan.Bioorg.Med.Chem Lett.2002,12,1375.
4.F.Yang,Y.Chen,W.H.Duan,C.Zhang,H.Zhu,J.Ding.Int.J.Cancer.2006,119,1184.
为了寻找更好活性的紫草素衍生物,我们设计了紫草素乙酰糖的衍生物,我们发现这一类化合物比紫草素具有更好的抗肿瘤活性,同时具备良好的耐药性,并未见有文献报道。
发明内容
本发明的目的是克服现有技术的不足,提供一种氨基甲酸紫草素酯及其制备方法和用途。
氨基甲酸紫草素酯的通式如下:
其中R=含有取代基团的直连烷烃或芳香基。
所述的氨基甲酸紫草素酯为:
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-苯基氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-甲基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-甲基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-环己基氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-氯苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N(2-氯乙基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-溴苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-甲氧基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-乙酰基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(2-O-乙酰基乙基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-硝基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-氟苯基)氨基甲酸酯或
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(三氯乙酰基)氨基甲酸酯。
氨基甲酸紫草素酯的制备方法是:1摩尔紫草素和1~2摩尔的异氰酸酯在甲苯中反应,反应温度为80~100℃,反应时间为10~15小时,柱层析分离得到氨基甲酸紫草素酯。
氨基甲酸紫草素酯用于制备具有抗肿瘤活性以及耐药性的药物。
本发明通过简单易行的方法制备氨基甲酸紫草素酯,并对氨基甲酸紫草素酯进行抗肿瘤活性和耐药性进行考察,发现其对肿瘤细胞株具有强烈的抑制作用,并证明具有很好的耐药性,是具有前途的抗肿瘤药物。
具体实施方式
本发明氨基甲酸紫草素酯的通式如下:
其中R=含有取代基团的直连烷烃或芳香基,优选化合物如下:
本发明的反应式如下:
本发明制备的氨基甲酸紫草素酯在细胞毒实验中发现对肿瘤细胞株具有强烈的抑制作用,并证明具有很好的耐药性,是具有前途的抗肿瘤药物。
抗肿瘤活性测定:
K562细胞使用添加10%胎牛血清的RPMI-1640培养液,K562/ADR细胞使用添加10%胎牛血清和1ug/mL阿霉素的RPMI-1640培养液,培养于含5%CO2的饱和湿度37℃恒温培养箱中。所有的化合物用DMSO溶解制成浓度为20mM的储备液,使用前用新鲜培养基稀释成相应的浓度。3000/孔的MCF-7和K562和K562/ADR的种板密度分别为8000和3000/孔,种板后直接用化合物处理。恒温箱中培养72小时后,每孔加20uL的5mg/mL的MTT(过滤除菌,遮光,4℃保存),37℃孵育4小时后,倾倒培养板内液体,每孔加入150uLDMSO,以溶解MTT形成的蓝紫色甲簪结晶,在570nm波长下用酶标仪检测吸光度值,计算不同化合物对各细胞的生长抑制率。
表1氨基甲酸紫草素酯细胞毒性
编号 | K562 | K562/Adr | Ratio |
Ar-sh | 4.91 | 4.92 | 1.002037 |
MT-sh | 3.76 | 4.8 | 1.276596 |
PT-sh | 4.9 | 4.86 | 0.991837 |
Hex-sh | 1.55 | 2.72 | 1.754839 |
3Chlo-sh | 2.1 | 2.16 | 1.028571 |
ChlEt-sh | 2.64 | 2.67 | 1.011364 |
3Brom-sh | 4 | 2.7 | 0.675 |
4Ome-sh | 4.32 | 2.8 | 0.648148 |
3Acp-sh | 2.43 | 3.68 | 1.514403 |
EtAc-sh | 3 | >5(~5) | |
4Flu-sh | 4.47 | 4.77 | 1.067114 |
Trichl-sh | 1.55 | 1.58 | 1.019355 |
实施例1
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-苯基氨基甲酸酯(Ar-sh)0.288g(1mmol)紫草素和异氰酸苯酯0.119g(1mmol)溶于10mL甲苯中,在80℃下反应15小时,蒸除溶剂,残余物柱层析分离,得到0.28g(69%)具有如下结构的标题化合物。
1H NMR(400MHz,CDCl3):δ12.60(s,1H),12.41(s,1H),7.37(d,J=8.0Hz,2H),7.31(m,2H),7.16(s,2H),7.06(m,2H),6.84(s,1H),6.03(m,1H),5.17(1H),2.66(m,1H),2.49(m,1H),1.70(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ177.7,176.2,167.6,167.1,152.0,148.2,137.2,135.9,132.8,132.6,131.2,129.0,123.7,118.5,117.6,111.7,111.5,70.4,32.8,25.6,17.9ppm;
实施例2
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-甲基苯基)氨基甲酸酯(Mt-sh)
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-苯基氨基甲酸酯(Ar-sh)0.288g(1mmol)紫草素和异氰酸-3-甲基苯酯0.266g(2mmol)溶于10mL甲苯中,在100℃下反应10小时,蒸除溶剂,残余物柱层析分离,得到0.28g(69%)具有如下结构的标题化合物。
1H NMR(400MHz,CDCl3):δ12.61(s,1H),12.4(s,1H),7.18(m,5H),7.05(s,1H),6.90(m,1H),6.74(s,1H),6.03(m,1H),5.18(m,1H),2.68(m,1H),2.53(m,1H),2.32(s,3H),1.71(s,3H),1.60(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ177.4,175.9,167.2,166.7,151.7,147.9,138.6,136.8,135.6,132.4,132.3,130.8,128.4,124.1,118.8,117.3,115.2,111.4,111.1,70.0,32.5,25.3,21.0,17.5ppm;
实施例3
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-甲基苯基)氨基甲酸酯(Pt-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.59(s,1H),12.42(s,1H),7.25(m,2H),7.16(m,2H),7.08(m,3H),6.80(s,1H),6.03(m,1H),5.17(m,1H),2.65(m,1H),2.52(m,1H),2.29(s,3H),1.69(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ178.1,176.6,167.5,167.0,152.2,148.5,136.0,134.7,133.4,132.8,132.7,131.3,129.6,118.6,117.8,111.8,111.6,70.4,33.0,25.8,20.7,18.0ppm;
实施例4
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-环己基氨基甲酸酯(Hex-sh)操作同实施例1
1H NMR(400MHz,CDCl3):δ12.59(s,1H),12.45(s,1H),7.18(s,2H),6.98(s,1H),5.93(m,1H),5.13(m,1H),4.72(d,J=8Hz,1H),3.44(t,J=4Hz,1H),2.63(m,1H),2.46(m,1H),1.94(m,2H),1.69(m,5H),1.56(m,4H),1.31(m,2H),1.17(m,3H)ppm;
13C NMR(100MHz,CDCl3):δ178.9,177.4,165.9,165.4,153.8,148.9,135.2,131.9,131.8,131.2,117.5,111.4,111.1,69.2,49.6,32.9,32.5,25.3,24.9,24.3,17.5ppm;
实施例5
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-氯苯基)氨基甲酸酯(3Chl-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.59(s,1H),12.41(s,1H),750(s,1H),7.17(m,4H),7.02(m,2H),6.91(s,1H),6.03(m,1H),5.16(m,1H),2.65(m,1H),2.53(m,1H),1.70(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ177.1,175.6,168.4,167.9,151.9,147.9,138.5,136.2,134.8,133.2,133.0,131.1,130.0,123.8,118.7,117.6,116.5,111.8,111.6,70.8,32.9,25.8,18.0ppm;
实施例6
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N(2-氯乙基)氨基甲酸酯(Chlet-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.58(s,1H),12.43(s,1H),7.18(s,2H),7.00(s,1H),5.96(dd,J=4.86.4Hz,1H),5.29(m,1H),5.13(t,J=7.2Hz,1H),3.63(m,2H),3.53(m,2H),2.61(m,1H),2.48(m,1H),1.69(s,3H),1.57(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ178.4,176.9,167.2,166.6,155.0,148.6,136.0,132.7,132.6,131.4,117.7,111.8,111.5,70.3,43.9,42.8,32.9,25.7,17.9ppm;
实施例7
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-溴苯基)氨基甲酸酯(3Brom-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.59(s,1H),12.41(s,1H),7.40(m,2H),7.28(m,2H),7.17(s,2H),7.04(s,1H),6.87(s,1H),6.03(m,1H),5.16(m,1H),2.67(m,1H),2.50(m,1H),1.69(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ177.2,175.6,168.3,167.8,152.0,147.9,136.5,136.2,133.1,132.9,131.9,131.9,131.1,120.0,117.6,117.5,116.3,111.8,111.5,70.7,32.9,25.7,18.0ppm;
实施例8
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-甲氧基苯基)氨基甲酸酯(4OMe-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.60(s,1H),12.43(s,1H),7.29(m,2H),717(s,2H),7.05(s,1H),6.85(m,2H),6.71(s,1H),6.02(m,1H),5.17(m,1H),3.77(s,3H),2.66(m,1H),2.53(m,1H),1.70(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ178.2,176.6,167.5,166.9,148.5,136.0,132.8,132.7,131.4,130.4,120.5,117.8,114.2,114.2,111.8,111.6,70.4,55.5,32.9,25.8,18.0ppm;
实施例9
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-乙酰基苯基)氨基甲酸酯(3Acp-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.60(s,1H),12.41(s,1H),7.97(m,1H),7.64(m,2H),7.42(m,1H),7.17(m,3H),7.06(s,1H),6.05(m,1H),5.17(m,1H),2.66(m,1H),2.60(s,3H),2.53(m,1H),1.69(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ197.8,177.4,175.9,168.1,167.6,152.2,148.0,138.0,137.8,136.2,133.1,132.9,131.2,129.4,123.6,123.0,118.1,117.6,111.8,111.6,70.7,32.9,26.7,25.8,18.0ppm;
实施例10
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(2-O-乙酰基乙基)氨基甲酸酯(Etac-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.56(s,1H),12.42(s,1H),7.16(s,2H),7.01(s,1H),5.92(m,1H),5.40(t,J=5.2Hz,1H),5.13(t,J=6.8Hz,1H),4.22(m,2H),3.94(m,2H),2.60(m,1H),2.48(m,1H),1.68(s,3H),1.56(s,3H),1.27(t,J=7.2Hz,3H)ppm;
13C NMR(100MHz,CDCl3):δ178.6,177.1,169.7,167.0,166.5,155.0,148.7,135.9,132.7,132.5,131.5,117.7,111.8,111.6,70.5,61.6,42.8,32.9,25.7,17.9,14.1ppm;
实施例11
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-氟苯基)氨基甲酸酯(4Flu-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.60(s,1H),12.42(s,1H),7.33(m,2H),7.17(s,2H),7.01(m,3H),6.81(s,1H),6.03(m,1H),5.16(m,1H),2.65(m,1H),2.52(m,1H),1.70(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ177.6,176.1,167.9,167.4,152.3,148.2,136.1,133.3,133.0,132.9,131.2,120.4,117.6,115.8,115.6,111.8,111.6,70.6,32.9,25.8,18.0ppm;
实施例12
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(三氯乙酰基)氨基甲酸酯(Trichl-sh)
操作同实施例1
1H NMR(400MHz,CDCl3):δ12.57(s,1H),12.44(s,1H),8.52(s,1H),7.17(m,2H),7.14(s,1H),6.15(m,1H),5.13(t,J=7.2Hz,1H),2.70(m,1H),2.60(m,1H),1.69(s,3H),1.59(s,3H)ppm;
13C NMR(100MHz,CDCl3):δ175.5,173.8,169.8,169.4,157.5,149.0,145.6,137.0,133.8,133.6,131.4,116.7,111.7,111.6,91.6,73.0,32.7,25.8,17.9ppm;
Claims (1)
1.一种氨基甲酸紫草素酯的制备方法,其特征在于1摩尔紫草素和1~2摩尔的异氰酸酯在甲苯中反应,反应温度为80~100℃,反应时间为10~15小时,柱层析分离得到氨基甲酸紫草素酯;所述的氨基甲酸紫草素酯为:
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-苯基氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-甲基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-甲基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-氯苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N(2-氯乙基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-溴苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-甲氧基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(3-乙酰基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(2-O-乙酰基乙基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-硝基苯基)氨基甲酸酯、
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(4-氟苯基)氨基甲酸酯或
1-(5,8-二羟基-1,4-萘醌-2-基)-4-甲基-3-戊烯基-N-(三氯乙酰基)氨基甲酸酯。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101531399A CN101671278B (zh) | 2009-09-21 | 2009-09-21 | 氨基甲酸紫草素酯及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101531399A CN101671278B (zh) | 2009-09-21 | 2009-09-21 | 氨基甲酸紫草素酯及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101671278A CN101671278A (zh) | 2010-03-17 |
CN101671278B true CN101671278B (zh) | 2012-06-27 |
Family
ID=42018726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101531399A Expired - Fee Related CN101671278B (zh) | 2009-09-21 | 2009-09-21 | 氨基甲酸紫草素酯及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101671278B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526018B (zh) * | 2010-12-30 | 2014-07-02 | 浙江大学 | 氨基甲酸紫草素酯在制备丙酮酸激酶抑制剂中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2831786A1 (de) * | 1978-07-19 | 1980-02-07 | Papageorgiou Vassilios | P-dihydroxynaphtochinonderivate und verfahren zu ihrer herstellung |
CN1112363A (zh) * | 1993-07-14 | 1995-11-22 | 安丙浚 | 制备5,8-二氢萘醌衍生物的方法,新的5,8-二氢萘醌衍生物和它们作为抗癌药的用途 |
-
2009
- 2009-09-21 CN CN2009101531399A patent/CN101671278B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2831786A1 (de) * | 1978-07-19 | 1980-02-07 | Papageorgiou Vassilios | P-dihydroxynaphtochinonderivate und verfahren zu ihrer herstellung |
CN1112363A (zh) * | 1993-07-14 | 1995-11-22 | 安丙浚 | 制备5,8-二氢萘醌衍生物的方法,新的5,8-二氢萘醌衍生物和它们作为抗癌药的用途 |
Non-Patent Citations (1)
Title |
---|
Vassilios P. Papageorgiou et al.The chemistry and biology of alkannin,shikonin,and related naphthazarin natural products.《Angewandte Chemie International Edition》.1999,第38卷(第3期),270-300. * |
Also Published As
Publication number | Publication date |
---|---|
CN101671278A (zh) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108358973B (zh) | 萘酰亚胺四价铂类化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN102258788A (zh) | 一种靶向传递阿霉素抗癌药的组装体及其制备方法 | |
CN104151391B (zh) | 一种具有抗肿瘤作用的齐墩果酸衍生物及其制备方法和用途 | |
CN101671376B (zh) | 紫草素乙酰糖及其制备方法和用途 | |
CN101671278B (zh) | 氨基甲酸紫草素酯及其制备方法和用途 | |
Salman et al. | Synthesis, characterization and biological application of dinuclear Cu (II) complexes of Schiff base ligands of galactochloralose and α-chloralose | |
CN110790695B (zh) | 苯偶酰腙-n-甲基-3-吲哚甲醛的合成及用途 | |
CN103232447B (zh) | 3-乙酰基-5-乙酰亚氨基-2-(n-吩噻嗪基)-1,3,4-噻二唑及其制备方法和应用 | |
CN101891794B (zh) | 一种具有抗肿瘤活性的熊果酸哌嗪类衍生物及其制备方法 | |
CN110156816B (zh) | 一种四氢吡唑并哌嗪类化合物及其制备方法及应用 | |
CN110746392B (zh) | 一类呋喃化合物在制备抗肿瘤药物中的应用 | |
CN107253949A (zh) | 一类硫杂吴茱萸次碱化合物及其在抗肿瘤药物中的应用 | |
CN113880872A (zh) | 一种喜树碱硼酸类化合物的制备及其在抗肿瘤方面的用途 | |
CN113321673A (zh) | 一种新白叶藤碱硼酸类化合物的制备方法和用途 | |
CN102584670B (zh) | 一种吲哚-3-甲醛缩苯二胺双席夫碱及其制备方法 | |
CN114644643A (zh) | 一类孪药及其合成方法和应用 | |
CN106798739B (zh) | 一种用于***疾病的药物 | |
CN110183471B (zh) | 一种哌嗪类衍生物及制备方法及应用 | |
CN102491934B (zh) | 羟基苯甲醛吲哚席夫碱及其制备方法和应用 | |
CN113387934B (zh) | 一种多芳基取代咪唑衍生物及其制备方法与应用 | |
CN103214429A (zh) | 1-取代苯基-3-(n-吩噻嗪基)丙-2-烯-1-酮及其制备方法和应用 | |
CN102503882B (zh) | 卤代苯甲醛吲哚席夫碱及其制备方法和应用 | |
CN113801107B (zh) | 一种具有抗肿瘤活性的柚皮素衍生物及其Ni(II)配合物的制备和应用 | |
CN109206473B (zh) | 一种c12、c13位取代齐墩果酸衍生物及其制备和应用 | |
CN113929669B (zh) | 一种新型橙皮素嘧啶腙衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120627 Termination date: 20170921 |
|
CF01 | Termination of patent right due to non-payment of annual fee |